β3 Adrenoceptor Agonism Prevents Hyperoxia-Induced Colonic Alterations
Biomolecules · 2023
DOI: 10.3390/biom13121755 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Luca Filippi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy. Hauptthemen laut MEDLINE: Ethanolamines, Hyperoxia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Meyer Children's Hospital, Ente Cassa di Risparmio di Firenze, Meyer Foundation, A. Meyer Children’s University Hospital, Florence, Italy.
Abstract (Originalsprache)
Oxygen level is a key regulator of organogenesis and its modification in postnatal life alters the maturation process of organs, including the intestine, which do not completely develop in utero. The β3-adrenoreceptor (β3-AR) is expressed in the colon and has an oxygen-dependent regulatory mechanism. This study shows the effects of the β3-AR agonist BRL37344 in a neonatal model of hyperoxia-driven colonic injury. For the first 14 days after birth, Sprague–Dawley rat pups were exposed to ambient oxygen levels (21%) or hyperoxia (85%) and treated daily with BRL37344 at 1, 3, 6 mg/kg or untreated. At the end of day 14, proximal colon samples were collected for analysis. Hyperoxia deeply influences the proximal colon development by reducing β3-AR-expressing cells (27%), colonic length (26%) and mucin production (47%), and altering the neuronal chemical coding in the myenteric plexus without changes in the neuron number. The administration of BRL37344 at 3 mg/kg, but not at 1 mg/kg, significantly prevented these alterations. Conversely, it was ineffective in preventing hyperoxia-induced body weight loss. BRL37344 at 6 mg/kg was toxic. These findings pave the way for β3-AR pharmacological targeting as a therapeutic option for diseases caused by hyperoxia-impaired development, typical prematurity disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy.
- Department of Experimental and Clinical Medicine, University of Florence, 50139 Florence, Italy.
- Imaging Platform, Department Experimental and Clinical Medicine, University of Florence, 50139 Florence, Italy.
- Department of Pediatric, Meyer Children's University Hospital, 50139 Florence, Italy.
- Division of Pediatric Oncology/Hematology, Meyer University Children's Hospital, 50139 Florence, Italy.
- Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
ORCID-Profile: Luca Filippi, Patrizia Nardini, Virginia Zizi, Camilla Fazi, Maura Calvani, Giacomo Cavallaro, Alessandro Pini
Förderung
- Meyer Children's Hospital
- Ente Cassa di Risparmio di Firenze
- Meyer Foundation, A. Meyer Children’s University Hospital, Florence, Italy
Zitieren
APA
Filippi, L., Nardini, P., Zizi, V., Molino, M., Fazi, C., Calvani, M., Carrozzo, F., Cavallaro, G., Giuseppetti, G., Calosi, L., Crociani, O., & Pini, A. (2023). β3 Adrenoceptor Agonism Prevents Hyperoxia-Induced Colonic Alterations. Biomolecules. https://doi.org/10.3390/biom13121755
Vancouver
Filippi L, Nardini P, Zizi V, Molino M, Fazi C, Calvani M, et al. β3 Adrenoceptor Agonism Prevents Hyperoxia-Induced Colonic Alterations. Biomolecules. 2023. doi:10.3390/biom13121755
BibTeX
@article{Filippi2023,
author = {Filippi, Luca and Nardini, Patrizia and Zizi, Virginia and Molino, Marta and Fazi, Camilla and Calvani, Maura and Carrozzo, Francesco and Cavallaro, Giacomo and Giuseppetti, Giorgia and Calosi, Laura and Crociani, Olivia and Pini, Alessandro},
title = {β3 Adrenoceptor Agonism Prevents Hyperoxia-Induced Colonic Alterations},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13121755}
}
EUVIMED